174 related articles for article (PubMed ID: 36445330)
1. COMMD3-Mediated Endosomal Trafficking of HER2 Inhibits the Progression of Ovarian Carcinoma.
Wang S; Liu Y; Li S; Chen Y; Liu Y; Yan J; Wu J; Li J; Wang L; Xiang R; Shi Y; Qin X; Yang S
Mol Cancer Res; 2023 Mar; 21(3):199-213. PubMed ID: 36445330
[TBL] [Abstract][Full Text] [Related]
2. Transcriptional analysis of the expression, prognostic value and immune infiltration activities of the COMMD protein family in hepatocellular carcinoma.
Wang X; He S; Zheng X; Huang S; Chen H; Chen H; Luo W; Guo Z; He X; Zhao Q
BMC Cancer; 2021 Sep; 21(1):1001. PubMed ID: 34493238
[TBL] [Abstract][Full Text] [Related]
3. Serotonin/HTR1E signaling blocks chronic stress-promoted progression of ovarian cancer.
Qin X; Li J; Wang S; Lv J; Luan F; Liu Y; Chen Y; Chen X; Zhao Y; Zhu J; Piao Y; Zhang W; Shi Y; Xiang R; Qu P; Wang L
Theranostics; 2021; 11(14):6950-6965. PubMed ID: 34093864
[No Abstract] [Full Text] [Related]
4. M2-like tumor-associated macrophages-secreted EGF promotes epithelial ovarian cancer metastasis via activating EGFR-ERK signaling and suppressing lncRNA LIMT expression.
Zeng XY; Xie H; Yuan J; Jiang XY; Yong JH; Zeng D; Dou YY; Xiao SS
Cancer Biol Ther; 2019; 20(7):956-966. PubMed ID: 31062668
[No Abstract] [Full Text] [Related]
5. The COMMD Family Regulates Plasma LDL Levels and Attenuates Atherosclerosis Through Stabilizing the CCC Complex in Endosomal LDLR Trafficking.
Fedoseienko A; Wijers M; Wolters JC; Dekker D; Smit M; Huijkman N; Kloosterhuis N; Klug H; Schepers A; Willems van Dijk K; Levels JHM; Billadeau DD; Hofker MH; van Deursen J; Westerterp M; Burstein E; Kuivenhoven JA; van de Sluis B
Circ Res; 2018 Jun; 122(12):1648-1660. PubMed ID: 29545368
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-7 inhibits tumor metastasis and reverses epithelial-mesenchymal transition through AKT/ERK1/2 inactivation by targeting EGFR in epithelial ovarian cancer.
Zhou X; Hu Y; Dai L; Wang Y; Zhou J; Wang W; Di W; Qiu L
PLoS One; 2014; 9(5):e96718. PubMed ID: 24816687
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of neratinib in the treatment of HER2/neu-amplified epithelial ovarian carcinoma in vitro and in vivo.
Menderes G; Bonazzoli E; Bellone S; Black JD; Lopez S; Pettinella F; Masserdotti A; Zammataro L; Litkouhi B; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
Med Oncol; 2017 May; 34(5):91. PubMed ID: 28397106
[TBL] [Abstract][Full Text] [Related]
8. Single-Cell RNA-Sequencing Atlas Reveals the Tumor Microenvironment of Metastatic High-Grade Serous Ovarian Carcinoma.
Deng Y; Tan Y; Zhou D; Bai Y; Cao T; Zhong C; Huang W; Ou Y; Guo L; Liu Q; Yin D; Chen L; Luo X; Sun D; Sheng X
Front Immunol; 2022; 13():923194. PubMed ID: 35935940
[TBL] [Abstract][Full Text] [Related]
9. α2,3-sialyltransferase type I regulates migration and peritoneal dissemination of ovarian cancer cells.
Wen KC; Sung PL; Hsieh SL; Chou YT; Lee OK; Wu CW; Wang PH
Oncotarget; 2017 Apr; 8(17):29013-29027. PubMed ID: 28423672
[TBL] [Abstract][Full Text] [Related]
10. SOCS7/HuR/FOXM1 signaling axis inhibited high-grade serous ovarian carcinoma progression.
Du Y; Xu X; Lv S; Liu H; Sun H; Wu J
J Exp Clin Cancer Res; 2022 May; 41(1):185. PubMed ID: 35624501
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin II type 2 receptor-interacting protein 3a inhibits ovarian carcinoma metastasis via the extracellular HMGA2-mediated ERK/EMT pathway.
Ping H; Guo L; Xi J; Wang D
Tumour Biol; 2017 Jun; 39(6):1010428317713389. PubMed ID: 28651497
[TBL] [Abstract][Full Text] [Related]
12. Biological and prognostic value of ETV5 in high-grade serous ovarian cancer.
Zhang L; Fu R; Liu P; Wang L; Liang W; Zou H; Jia W; Tao L
J Ovarian Res; 2021 Nov; 14(1):149. PubMed ID: 34736492
[TBL] [Abstract][Full Text] [Related]
13. TRAF4 promotes the malignant progression of high-grade serous ovarian cancer by activating YAP pathway.
Luo X; Cao J; Zhang C; Huang H; Liu J
Biochem Biophys Res Commun; 2022 Oct; 627():68-75. PubMed ID: 36029535
[TBL] [Abstract][Full Text] [Related]
14. Dacomitinib, a pan-inhibitor of ErbB receptors, suppresses growth and invasive capacity of chemoresistant ovarian carcinoma cells.
Momeny M; Zarrinrad G; Moghaddaskho F; Poursheikhani A; Sankanian G; Zaghal A; Mirshahvaladi S; Esmaeili F; Eyvani H; Barghi F; Sabourinejad Z; Alishahi Z; Yousefi H; Ghasemi R; Dardaei L; Bashash D; Chahardouli B; Dehpour AR; Tavakkoly-Bazzaz J; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
Sci Rep; 2017 Jun; 7(1):4204. PubMed ID: 28646172
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Outcome of Mesenchymal Transition Biomarkers in Correlation with EGFR Expression in Epithelial Ovarian Carcinoma Patients.
Kamal IM; Temerik DF; Yassin EH; Mosad E; A H; Hussien MT
Asian Pac J Cancer Prev; 2022 Dec; 23(12):4213-4225. PubMed ID: 36580004
[TBL] [Abstract][Full Text] [Related]
16. Cysteine-Rich Intestinal Protein 1 Served as an Epithelial Ovarian Cancer Marker via Promoting Wnt/
Liu Y; Li W; Luo J; Wu Y; Xu Y; Chen T; Zhang W; Fu F
Dis Markers; 2021; 2021():3566749. PubMed ID: 34413913
[TBL] [Abstract][Full Text] [Related]
17. GATA3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma.
El-Arabey AA; Denizli M; Kanlikilicer P; Bayraktar R; Ivan C; Rashed M; Kabil N; Ozpolat B; Calin GA; Salama SA; Abd-Allah AR; Sood AK; Lopez-Berestein G
Cell Signal; 2020 Apr; 68():109539. PubMed ID: 31935430
[TBL] [Abstract][Full Text] [Related]
18. Investigating the Association between COMMD3 Expression and the Prognosis of Hepatocellular Carcinoma.
Cheng W; Cheng Z; Zhang C; Weng L; Xing D; Zhang M
J Cancer; 2022; 13(6):1871-1881. PubMed ID: 35399735
[TBL] [Abstract][Full Text] [Related]
19. Prolactin signaling drives tumorigenesis in human high grade serous ovarian cancer cells and in a spontaneous fallopian tube derived model.
Karthikeyan S; Russo A; Dean M; Lantvit DD; Endsley M; Burdette JE
Cancer Lett; 2018 Oct; 433():221-231. PubMed ID: 29981811
[TBL] [Abstract][Full Text] [Related]
20. Kindlin-2 inhibits serous epithelial ovarian cancer peritoneal dissemination and predicts patient outcomes.
Ren C; Du J; Xi C; Yu Y; Hu A; Zhan J; Guo H; Fang W; Liu C; Zhang H
Biochem Biophys Res Commun; 2014 Mar; 446(1):187-94. PubMed ID: 24583125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
